<DOC>
	<DOCNO>NCT00555451</DOCNO>
	<brief_summary>The objective study evaluate safety , tolerance pharmacokinetics HE3286 administer daily 28 day obese adult subject assess potential activity HE3286 decrease insulin resistance . An open-label cohort 6 patient type II diabetes mellitus treat 10 mg ( 5 mg BID ) .</brief_summary>
	<brief_title>Safety , Pharmacokinetics Potential Activity HE3286 Obese Adult Subjects</brief_title>
	<detailed_description>HE3286 potentially new mechanism action may improve current therapeutic option available patient metabolic disorder , inflammatory autoimmune disease . In preclinical experiment , HE3286 show anti-inflammatory activity associate corticosteroid without side effect know corticosteroid use , immune suppression bone loss . HE3286 demonstrate glucose-lowering insulin-enhancing effect several preclinical mouse rat model insulin resistance . In experiment , HE3286 lower blood glucose level prevent progression hyperglycemia HE3286 appear enhance insulin sensitivity .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>Main Males females 18 65 year age Body mass index females 29 35 kg/m2 37 kgm2 male Fasting blood glucose level &lt; 126 mg/dL screen 2 hour postprandial ( follow 75 gram glucose ) blood glucose 140 200 mg/dL Normal thyroid stimulate hormone without thyroid replacement therapy Fasting triglyceride &lt; 350 mg/dL For female reproductive potential , agree avoid pregnancy study 3 month follow study completion , negative serum and/or urine pregnancy test , use acceptable method birth control Nonsmoker smoke 6 month prior screen visit No history alcohol abuse within 2 year Negative drug screen screen baseline Stable weight ( +/ 5 % ) ; history weight loss gain ( &gt; 10 % body weight ) Must provide voluntary , write , informed consent prior screen evaluation Must able swallow capsule Main Marked prolongation QT/QTc interval history additional risk factor Torsades de Pointes screen baseline Positive HIV , HAV , HBV HCV History clinically significant cardiovascular , hepatic , respiratory renal endocrine disorder History breast and/or prostate cancer Clinically significant neurological psychiatric condition , uncontrolled hypertension , clinically significant unstable medical abnormality , chronic disease active , serious clinical infection condition Personal family member breast and/or prostate cancer Malignancy within past 5 year except successfully treat basal cell carcinoma skin Personal and/or family history venous thromboembolism History stroke and/or heart attack Medication prohibit study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>phase I</keyword>
	<keyword>safety</keyword>
	<keyword>tolerance</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>obese</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>